Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $76.5 million.

  • Neurocrine Biosciences' Change in Accured Expenses fell 103.49% to $76.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $160.2 million, marking a year-over-year increase of 26912.44%. This contributed to the annual value of $160.2 million for FY2025, which is 26912.44% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Change in Accured Expenses of $76.5 million as of Q4 2025, which was down 103.49% from $55.8 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Change in Accured Expenses peaked at $124.4 million during Q3 2023, and registered a low of -$98.3 million during Q4 2023.
  • Its 4-year average for Change in Accured Expenses is $20.3 million, with a median of $15.5 million in 2025.
  • The largest annual percentage gain for Neurocrine Biosciences' Change in Accured Expenses in the last 5 years was 17863.68% (2024), contrasted with its biggest fall of 46728.4% (2024).
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Change in Accured Expenses stood at $11.0 million in 2021, then tumbled by 993.64% to -$98.3 million in 2023, then soared by 178.64% to $77.3 million in 2024, then fell by 1.03% to $76.5 million in 2025.
  • Its Change in Accured Expenses was $76.5 million in Q4 2025, compared to $55.8 million in Q3 2025 and $15.5 million in Q2 2025.